minorities

In episode 1581, Jack and Miles are joined by award winning journalist, Aymann Ismail, to discuss…How The Media Has Been Covering The War In Gaza From The Start and more!

1. Intensified Israeli Surveillance Has Put the West Bank on Lockdown
2. Posting Empathy for Gaza Ended One of Her Friendships. An Expert on This Thinks That’s Fine.
3. Haaretz.Com
4. The Origins of the Gaza Strip, and the Israeli Communities Nestled by It

Aymann Want's You To See This: That New KFC...?

LISTEN: Greg Abbott's Maxi Pad by Farmer's Wife

See omnystudio.com/listener for privacy information.

This is a part of the non-profit series where I highlight great members of the tech community who play a significant role in running a non-profit.

Valerie is a self-taught developer who is now an engineering manager and the founder of Tech by Choice, a non-profit that helps underrepresented groups enter, stay and thrive in tech.

Valerie talks about her experience as a manager and her work with Tech by Choice. She discusses her biggest challenges as a manager, her goals for the future, and her advice for others who are interested in entering the tech industry.

As the founder of Tech By Choice, Valerie shares her personal stories that inspired the creation of Tech By Choice, the challenges of running a non-profit, the impact she's seeing in the community, and exciting projects that will be launching soon.

https://www.techbychoice.org/donate
https://mailchi.mp/081b79193143/understand-your-taxes-end-of-year-tax-strategies

Valerie's previous interview. https://www.levelupfinancialplanning.com/the-wealth-of-being-in-tech-with-valerie/

Courtesy of Athira Pharma, Psychiatrist and Medical Director Bernardo Ng of the Sun Valley Research Center joins Suzanne to talk about how they reach out to the community to find people to participate in Alzheimer's clinical trials, particularly in underserved groups such as Latino populations in the United States.

Dr. Ng says, "We've done a lot of different things and we've learned as we go. What we do constantly is to participate in what's called health fairs. So the health department, some federal clinics, some schools, and the local community college periodically put together health fairs, and some of my people go there. It's old fashioned, mouth to mouth. And we do what we call a free memory test, which is a pen and pen paper test with questions.

"We have a few long-term retirement homes. If the owners or the administrative team allow us, we go visit them and give them a talk and say what we do. That has been it is very hard to predict. Sometimes it works, sometimes it doesn't. 

"And then we suddenly discovered that Facebook works, and that this population likes Facebook. So we hired a firm that manages our social media, we run ads in English and in Spanish. So the same message we put it one day in English the other day in Spanish. If you click, it asks you, do you agree to be called by a prescreening team. There's these young people who are very good on the phone, and bilingual, and they're very kind and patient, and they talk to the people that have clicked. Those calls can get very long, and more times than not, they're very well received. The moment they hear the word 'research,' there is like a pause. So we, we've turned our people to be more informative about it. You know, you participate voluntarily, you can get out of the trial any time you want. Little by little, we're getting people to contact us that way."

Contact the Sun Valley Research Center in southern California at (760) 545-0123.

Learn more:
* Sun Valley Research Center: https://sunvalleyb.com/
* Athira Pharma: https://www.athira.com/
* Bernardo Ng: https://sunvalleyr.com/ourteam/bernardo-ng-md/
* Hear more Alzheimer's-related podcasts from Athira Pharma: https://answersforelders.com/athira-pharma/

Answers for Elders is part of the SeniorResource Network: https://www.seniorresource.com/
Check out our affiliate podcast Alzheimer’s Speaks: https://alzheimersspeaks.com/

See omnystudio.com/listener for privacy information.

Courtesy of Athira Pharma, Psychiatrist and Medical Director Bernardo Ng of the Sun Valley Research Center joins Suzanne to talk about why Latinos are often hesitant to participate in Alzheimer's clinical trials.

Dr. Ng says, "We were talking about access earlier on, and that's one of the things that we're trying to overcome, by settling in an area that has little services. Other highly populated Hispanic areas may not have clinical sites like that.

"The other one is certainly the stigma that we have talked about. The fear of, or just the thought of, being a subject in the research trial, because that sounds wrong or sounds fishy. 

"And the other one is the denial, or fear of being diagnosed with Alzheimer's. Many people prefer to say that is normal aging, and a normal dementia for older people, which for years now, we know that that term does not exist anymore. I try to compare it with conditions like osteoporosis. You know, the bones become thin, it's normal that they become thin. Now, there is a point when the bones are just too thin, that's not normal, and requires treatment, because it carries health risks. So the same thing, being not able to memorize things, or to speak. Well, that's manifestations of the deterioration of the brain, and that's illness, and we call it Alzheimer's."

"I think [eventually] society is gonna look at this a different way. It's not such a sentence now for, you know, people with cancer, right? Especially, for example, with breast cancer. The progress has been humongous. So I look forward to the day we're gonna get there with Alzheimer's."

But there is a health care gap. Dr. Ng says, "The community I'm at is very peculiar, because it is 80% Latino, so it's very hard to compare how faster are the other 20% services. But I can tell you that a lot of these people that we're talking about don't have private insurance. Some of them are Medicare and Medicaid, and getting approved for surgery, for example for a knee replacement, they have to wait four or six months to get approved. I can't imagine now, with these antibody treatments that we have, how long it's gonna be to even get them approved. Which underscores the greater opportunity that it is to participate in a clinical trial, and will be sooner and faster than getting one of the approved treatments."

Contact the Sun Valley Research Center in southern California at (760) 545-0123.

Learn more:
* Sun Valley Research Center: https://sunvalleyb.com/
* Athira Pharma: https://www.athira.com/
* Bernardo Ng: https://sunvalleyr.com/ourteam/bernardo-ng-md/
* Hear more Alzheimer's-related podcasts from Athira Pharma: https://answersforelders.com/athira-pharma/

Answers for Elders is part of the SeniorResource Network: https://www.seniorresource.com/
Check out our affiliate podcast Alzheimer’s Speaks: https://alzheimersspeaks.com/

See omnystudio.com/listener for privacy information.

Courtesy of Athira Pharma, Psychiatrist and Medical Director Bernardo Ng of the Sun Valley Research Center joins Suzanne to talk about specific challenges for the Latino community in signing up for Alzheimer's clinical trials.

What are the specific challenges for Alzheimer's in the Latino community? Dr. Ng says, "One of the things about the Latino community is that they trust their doctors blindly, I'll trust whatever he or she tells me to do. And then when you put on the table, the option that we don't have any more treatments for you, or you keep on getting worse, or we detected that this is going on, this would be a good time for you to participate in a clinical trial, to confirm that you do have or don't have Alzheimer's. At that point they say, well, but why aren't you treating me with the usual things? Why a research trial? And the word research is very heavy, right?

"We need to make a greater effort to communicate the fact that, if anything, clinical trials are even more strict. When a molecule has passed so many tests already, that it's proven to be safe. You're in a clinical trial. You're observed, supervised, your blood test or urine tests are done more frequently. Brain scans if necessary. But then it feels like it's too invasive, and it's hard. [It was just] until a couple of years ago that the first antibody was approved for Alzheimer's, and just this year, another one. Before that, we've been prescribing the same medications for about 20 years. So we're so excited and so optimists think about the fact that there are more trials going on. They have to prove that they work or not work, but there will be more options for our patients."

"Let's say the medication doesn't work for you, or maybe we find out later on that you were on placebo, right? Whatever you did is already adding to the information, to the data, so that other people can benefit in the future. And you know what, the Latino population likes that they are able to help others. And that has helped us overcome some of the fears. And the people that do participate, they said, look, I'm gonna do whatever. I know this may not help me right now, but unless we do this, we're not gonna be able to help other people."

Dr. Ng explains how a treatment gets developed to the point of being ready for a clinical trial. "This perfect chain of events that has to happen. Yes, some people in a laboratory somewhere, working with rats, figure out that there's this molecule. They are super genius people, right, they come up with these formulas, tested with electronic microscopes. And then they start pushing that molecule forward, right? Then [it's tested] with humans who are healthy and ok, well, you know, it's fine, it's safe. Let's move forward. By the time we participate, these are usually phase 3 studies, sometimes phase 2, but usually phase 3, molecules have walked a long pathway already. So at that moment, we know a lot about their safety, that it's tolerable, and maybe we participate in studies where they're trying to figure out the right dose.

"And another thing I wanna mention about placebo, more and more the placebo phases of the studies have become shorter. That's only prove the concept. But from then on, most of the studies now have an open label section, where everybody sooner or later will receive the benefit of being on the active medication. And that also allow us to be able to see safety in the long run. So by the time I'm offering this to my patients. I'm very confident. A lot of molecules don't make it to phase 3 and, and the ones that do are worth moving forward and completing the whole process."

Contact the Sun Valley Research Center in southern California at (760) 545-0123.

Learn more:
* Sun Valley Research Center: https://sunvalleyb.com/
* Athira Pharma: https://www.athira.com/
* Bernardo Ng: https://sunvalleyr.com/ourteam/bernardo-ng-md/
* Hear more Alzheimer's-related podcasts from Athira Pharma: https://answersforelders.com/athira-pharma/

Answers for Elders is part of the SeniorResource Network: https://www.seniorresource.com/
Check out our affiliate podcast Alzheimer’s Speaks: https://alzheimersspeaks.com/

See omnystudio.com/listener for privacy information.

Courtesy of Athira Pharma, Psychiatrist and Medical Director Bernardo Ng of the Sun Valley Research Center joins Suzanne to talk about Alzheimer's clinical trials, particularly in underserved groups such as Latino populations in the United States.

Dr. Ng is a Mexicali native who started his private practice in Imperial County in 1994. He became a Medical Doctor at the University of Nuevo Leon in 1987. After completing his year of social service in the city of Monterrey in 1988, he entered specialized training in Psychiatry, in El Paso Texas in 1989 and continued in San Diego California in 1992. Dr. Ng is currently the principal investigator for Sun Valley Research Center.

Dr. Ng says, "Clinical trials are the core of progress in pharmaceutical treatments. Most medical conditions do not get treated only with medications. There are many other forms of treatment, but in the particular case of medications, it is only with medical clinical trials that prove or not prove that the medication actually works. And the problem with the the lack or the insufficient participation of Latinos in clinical trials, specifically in dementia, is impressive. As you know, Latinx are the largest minority in the US — 16 to 18% of the population. Participation of Latinos in clinical trials for Alzheimer's is anywhere from 1 to 2%. So that tells you how hard it is to ascertain that whatever is approved under those conditions will work the same both for efficacy and safety in the Latino population.

“Participating in clinical trials has a component of not enough information, not knowing the importance of why it is to participate, and fear. Thought of participating in a clinical trial and voluntarily putting yourself through a medication that has not been approved may sound scary, but the reality is that that's how, number one: progress occurs, and number two: you can actually access a treatment years before it's available in regular pharmacies. The Latino population in this country feel distant to that."

Suzanne says, "You hear the stories of decades ago ,when there were trials going on, a lot of the placebos and stuff went to people of color, which really is unfair."

D. Ng replies, "I'm very glad that you mentioned that because any of us interested in participating in the execution of clinical trials have to go through rigorous training, even before being approved or hired for any of them, which is called Good Clinical Practices. And it speaks a lot about this history that you're talking about, how trials in the 20th century happened unethically, right? And how they put people of color through tests without having received their consent, without informing them of what was gonna happen. And yes, I think that has left a scar in our minority populations in the country. I think it's very useful that media like this can inform people of how much that has changed, evolved. Every single step is supervised by an ethical review committee, any step is approved by the FDA."

"Alzheimer's is my passion. I've been treating older people for a long time, and there's some peculiar peculiarities about the Latino or Hispanic population in this country that they live longer, which is interesting. Some time ago, it was called the Hispanic Paradox or the Latino paradox. With less access to care, they live longer — how is that possible? But it turns out that when you look into the detail, they may live longer on average, but also with less quality of life, or more morbidity, with more level of disease, and among other things, lack of access. But then also lack of knowledge that some things can be treated earlier. In the case of Alzheimer's, many times they say, well, you know, it's part of aging that he or she starts forgetting things. And transmitting the message that what we're talking about is a disease that early on starts to cause some changes that can be manifested. Very subtle changes may already be announcing a disease. A lot of people of my ethnic background look at it as, if you don't ask, if you don't know, it's better. It's part of a cultural thing that has gone for the different generations and we're trying to change it. That's part of our mission, educate the community, bring services, bring trials to their door."

Contact the Sun Valley Research Center in southern California at (760) 545-0123.

Learn more:
* Sun Valley Research Center: https://sunvalleyb.com/
* Athira Pharma: https://www.athira.com/
* Bernardo Ng: https://sunvalleyr.com/ourteam/bernardo-ng-md/
* Hear more Alzheimer's-related podcasts from Athira Pharma: https://answersforelders.com/athira-pharma/

Answers for Elders is part of the SeniorResource Network: https://www.seniorresource.com/
Check out our affiliate podcast Alzheimer’s Speaks: https://alzheimersspeaks.com/

See omnystudio.com/listener for privacy information.

In this episode, Tudor welcomes Georgia State Representative Mesha Mainor, who recently made headlines for leaving the Democratic Party and joining the Republican Party. They discuss Mainor's decision, her determination to run for office again, and her advocacy for school choice. The conversation also touches on the low proficiency levels in reading and math in school districts, the importance of education and parental involvement, and the connection between education and crime rates. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more visit TudorDixonPodcast.com

See omnystudio.com/listener for privacy information.

In this episode, Alfredo Ortiz and Elaine Parker interview nationally syndicated radio host and small business owner, Carl Jackson. They discuss the recent economic news, including the Consumer Price Index and core inflation, as well as the impact on grocery prices. They also delve into the jobs report, expressing concern about small business owners putting hiring plans on hold due to economic uncertainty. Alfredo and Elaine critique President Biden's job creation claims and discuss the impact of inflation on small businesses. They also touch on their personal experiences as minorities in the Republican Party and the importance of hard work and entrepreneurship. Main Street Matters is part of the Salem Podcast Network - new episodes debut every Wednesday & Thursday. For more info visit jobcreatorsnetwork.com

See omnystudio.com/listener for privacy information.

Dylan Moore of Irida TV interviews Semi Bird who is running for Governor in Washington State for 2024 on the Republican ticket.

Dylan and Semi discuss hot issues in Washington State, the details of the path to victory, and the nuance of how to actually run the State from the governor's seat once you're in charge. An in depth interview that really gives Semi the opportunity to express himself and his solutions that you don't want to miss!

Notes:

• Semi Bird for Governor: https://www.birdforgovernor.com/
• Find more of our content: https://irida.tv/

 This week’s show is about everything New York City…after a fashion. We have a report about the obituary department in the New York times and their focus on illuminating why the lives they feature are significant. Along with a bit of schmaltz we look at digital memories and the meaning that they can have to people. 

Follow us on Facebook | Instagram | Email us at mail@every1dies.org

Click on this link to Rate and Review our podcast!

मोदी सरकार के लिए पिछले कुछ सालों से मानवाधिकार एक ऐसा मुद्दा बन गया है जिसकी वजह से इसकी किरकिरी होती रही है. एक बार फिर से इस विषय को लेकर Human Rights Watch संस्था ने अपनी वैश्विक रिपोर्ट में कहा है कि भारत सरकार ने एक्टिविस्ट समूहों और मीडिया पर हमले तेज़ कर दिए हैं. ह्यूमन राइट्स वॉच ने 100 से ज़्यादा देशों में मानवाधिकारों की स्थिति को लेकर अपनी वैश्विक रिपोर्ट जारी की है. 712 पन्नों की इस रिपोर्ट में कहा गया है कि हिंदू राष्ट्रवादी भारतीय जनता पार्टी की सरकार ने मुसलमान और अन्य अल्पसंख्यकों को दबाने के लिए अपमानजनक और भेदभावपूर्ण नीतियां अपनाई हैं. इस विडियो में हम Human Rights Watch संस्था के बारे में जानेंगे साथ ही यह भी जानेंगे के संस्था ने अपनी रिपोर्ट में भारत के लिए कौन से बातें कहीं हैं. 

This week, Hannah is back in the chair and is joined by Leo Devine and Amardeep Bassey to discuss the week’s top religious stories. Following on from a discussion on the Koh-i-Noor diamond and its potential contentious role in the coronation, royal expert Catherine Pepinster helps to shed light on the potential inclusivity of the ceremony to be held in May next year.

Azim Ahmed who, as a Muslim representative, took part in the Welsh national service to mark the Queen’s death, speaks about his hopes for a service that properly reflects the nation’s religious diversity. Yahya Birt also joins the podcast to talk about his recent report for the Ayaan Institute on the plight of minority Muslims around the world.

Links

Website: https://religionmediacentre.org.uk/

Twitter: https://twitter.com/RelMedCentre/

LinkedIn: https://www.linkedin.com/company/religion-media-centre/

YouTube: https://www.youtube.com/channel/UCthZf6RVTqJki6oTQTB6qmw

Contact Information

info@religionmediacentre.org.uk
(+44) 0203 970 0709

“Conversations that Matter” is a monthly online series from the McKinney Center. In each “Conversation” two local guests will explore their own culture and perspective, and talk to each other about what makes them unique, discover their similarities, and explore their differences. They will look at where their lives might intersect personally and in the community. The goal of each “Conversation that Matters” is for guests and participants to hear real stories, from real neighbors.
The next event in this series will feature Reverend Tiffany Sapp and Edward Wolff. This conversation will be moderated by Michelle Treece and guest moderator, Brittany Butler. It will take place via Zoom on August 12, at 7pm. Register at mckinneycenter.com.
Reverend Tiffany Sapp grew up in the mobile life of an Air Force brat and got to experience a variety of American culture and religious identities, but often returned to the Tri-Cities during the summers to visit her grandparents’ farm in Hidden Valley. While attending college at nearby Carson-Newman College and then seminary at Duke Divinity School, Rev. Tiffany had a sense that she wanted to be a minister. In 2018 Rev. Tiffany came to Holston Valley Unitarian Universalist Church as an intern minister and rediscovered her love for this area and its people. After completion of the internship, she went on to serve in a rigorous Clinical Pastoral Education Residency at Johnson City Medical Center. Rev. Tiffany lives in Gray TN along with her tugboat captain husband, their artsy middle school daughter, a corgi, a calico cat, and a ball python. When she’s not planning religious services or doing pastoral care visits, Rev. Tiffany enjoys cooking, hiking, and painting.
Ed Wolff is a retired ordained minister, living in Jonesborough for 17 years. In the past, he has been active in lifting awareness of climate change and the need for all citizens to have adequate medical benefits. Presently, he hosts Black/White Dialogue and is Treasurer of the Johnson City/Washington County NAACP. With the struggle to develop an Equity and Inclusion Advisory Board in the area, he is working with a small group to develop grassroots support through processes of bringing individuals of different perspectives together to understand the need for community unity.
This monthly series is inspired by the Diversity & Equity Subcommittee at the McKinney Center, and their desire to highlight the experiences of all voices in Washington County, Tennessee, with an intention to include marginalized groups. By showcasing these conversations, the Diversity & Equity subcommittee hopes to open doors to new ideas and perspectives amongst our very own neighbors. Questions such as, “What was your experience in grade school and how did that make you feel?” or, “Have you experienced exclusion or racism?” For many of us, the answers are different and unique. The McKinney Center believes it is time to talk about our experiences and share them.
There is value in uplifting these stories so that we may learn from one another. Then, after hearing from one another our moderators and guest conversationalists will give insight on how to move forward.